On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 44:29 Is Myostatin Still a Potential Therapeutic Target? (October 2018) 6 years ago Research & Clinical Trial Webinars,Webinars 1:00:51 Puberty and Duchenne (September 2018) 6 years ago Care Webinars,Webinars 1:09:04 HOPE-2 Duchenne Clinical Trial – Capricor (July 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:01:35 Introducing PPMO – Sarepta Therapeutics (May 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 50:18 Roche/Genentech Anti-Myostatin Adnectin RG6206 in Duchenne (May 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 49:43 NS Pharma’s Exon 53 Skipping Program Update (April 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:01:32 Gene Therapy: A Closer Look (March 2018) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 1:02:50 Pulmonary Care in Adults with Duchenne (March 2018) 7 years ago Care Webinars,Webinars «1…1516171819…26»Page 17 of 26